178 replies to this topic

[ImmInst]

Aastrom to Present Results of Phase 2a Clinical Trial of Ixmyelocel-T in ...
MarketWatch (press release) - 12 hours ago

ANN ARBOR, Mich., May 7, 2012 (GlobeNewswire via COMTEX) -- Aastrom Biosciences, Inc. (UTD:ASTM) , the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced ...

Aastrom To Present Results Of Phase 2a Clinical Trial Of Ixmyelocel-T - NASDAQ

View the full article

[ImmInst]

Aastrom to Present Results of Phase 2a Clinical Trial of Ixmyelocel-T in ...
MarketWatch (press release) - 16 hours ago

ANN ARBOR, Mich., May 7, 2012 (GlobeNewswire via COMTEX) -- Aastrom Biosciences, Inc. (UTD:ASTM) , the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced ...

Aastrom To Present Results Of Phase 2a Clinical Trial Of Ixmyelocel-T - NASDAQ

View the full article

[ImmInst]

Aastrom to Present Results of Phase 2a Clinical Trial of Ixmyelocel-T in ...
MarketWatch (press release) - 20 hours ago

ANN ARBOR, Mich., May 7, 2012 (GlobeNewswire via COMTEX) -- Aastrom Biosciences, Inc. (UTD:ASTM) , the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced ...

Aastrom To Present Results Of Phase 2a Clinical Trial Of Ixmyelocel-T - NASDAQ

View the full article

[ImmInst]

RegMed Competitive and Market Intelligence 5/7/12, stocks struggle as short ...
Proactive Investors USA & Canada - May 7, 2012

Today's Gospel: This has been a bad stretch for the RegMed universe and the economy as a whole. One after the other, companies and their CEO's are being gutted or delayed by FDA regulators while traders - escorted by a volatile market are squealing ...

View the full article

[ImmInst]

RegMed Competitive and Market Intelligence 5/7/12, stocks struggle as short ...
Proactive Investors USA & Canada - May 7, 2012

Today's Gospel: This has been a bad stretch for the RegMed universe and the economy as a whole. One after the other, companies and their CEO's are being gutted or delayed by FDA regulators while traders - escorted by a volatile market are squealing ...

View the full article

[ImmInst]

RegMed Competitive and Market Intelligence 5/7/12, stocks struggle as short ...
Proactive Investors USA & Canada - May 7, 2012

Today's Gospel: This has been a bad stretch for the RegMed universe and the economy as a whole. One after the other, companies and their CEO's are being gutted or delayed by FDA regulators while traders - escorted by a volatile market are squealing ...

View the full article

[ImmInst]

Aastrom To Present Results Of Phase 2a Clinical Trial Of Ixmyelocel-T
NASDAQ - May 7, 2012

(RTTNews.com) - Aastrom Biosciences Inc. (ASTM) announced that results from the company's Phase 2a clinical trial of ixmyelocel-T in the treatment of dilated cardiomyopathy or DCM will be presented at the Society for Cardiovascular Angiography and ...

View the full article

[ImmInst]

Stem Cell Biotechs Report 2011 Year In Review: Part II
Seeking Alpha - May 7, 2012

In part I of this series, Neostem (NBS) and Aastrom (ASTM) stood out in a field of 6 stem cell biotechs with their advancing trials, recent financing, manufacturing capabilities and/or current revenue generation (not profitability as this will likely ...

View the full article

[ImmInst]

RegMed Competitive and Market Intelligence 5/7/12, stocks struggle as short ...
Proactive Investors USA & Canada - May 7, 2012

Today's Gospel: This has been a bad stretch for the RegMed universe and the economy as a whole. One after the other, companies and their CEO's are being gutted or delayed by FDA regulators while traders - escorted by a volatile market are squealing ...

View the full article

[ImmInst]

Small Biotechs Like Aastrom Biosciences and Geron Likely to Benefit From New ...
MarketWatch (press release) - 5 hours ago

NEW YORK, NY, May 09, 2012 (MARKETWIRE via COMTEX) -- In recent months the Biotech Industry has become a hotbed of Merger and Acquisition (M&A) activity and speculation.

View the full article

[ImmInst]

Webcast Alert: Aastrom to Host First Quarter 2012 Investor Call on May 10, 2012
MarketWatch (press release) - May 7, 2012

ANN ARBOR, Mich., May 7, 2012 (GlobeNewswire via COMTEX) -- Aastrom Biosciences, Inc. (UTD:ASTM) , the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announces the ...

Aastrom to Present Results of Phase 2a Clinical Trial of Ixmyelocel-T in ... - GlobeNewsWire (press release)

View the full article

[ImmInst]

Stem Cell Biotechs Report 2011 Year In Review: Part I
Seeking Alpha - May 7, 2012

The biotech sector is comprised of a host of small pharmaceuticals striving to make their mark in the lives of the patients they hope to save, heal, alleviate symptoms for or help in one form or another.

View the full article

[ImmInst]

RegMed Competitive and Market Intelligence 5/11/12, stocks mixed, sector ...
Proactive Investors USA & Canada - 2 hours ago

Mid-Day Market Commentary: Stocks extended their gains Friday, thanks to a better-than-expected consumer sentiment report. The CBOE Volatility Index slipped below 19.

View the full article

[ImmInst]

Brief Review Of A Few Biotechs
Seeking Alpha - 3 hours ago

The following is a review of three biotech stocks with potential for growth. Amarin (AMRN), Osiris (OSIR and Abbott (ABT) are three companies with either recent breakthroughs, a catalyst, or a possible place to ride out a coming storm.

View the full article

[ImmInst]

Stem Cell Hype Has Yet To Breed Profits
Seeking Alpha - 8 hours ago

Over the past few years, stem cell therapies have emerged as an intriguing new frontier in biotechnology research as scientists have begun exploring ways to monetize stem cells' unique plasticity.

View the full article

[ImmInst]

Hope fading but, will prayers work for a return of focus to sector?
Proactive Investors USA & Canada - 3 hours ago

Mid-Day Market Commentary: Some … RegMed stocks extended a few gains on Tuesday … as investors haven't quite shrugged off worries over the euro zone and despite some tepid economic reports.

View the full article

[ImmInst]

Biotech Ideas That Will Change the World: Patrick Cox
International Business Times - 1 hour ago

For Patrick Cox, disruptive technologies drive change and harbor opportunity. Cox, editor of Breakthrough Technology Alert and Technology Profits Confidential, and a contributor to The Daily Reckoning, strives to find novel ideas in small-cap companies ...

View the full article

[ImmInst]

BioLife, Shire, Others Turning Regenerative Medicine Industry from ...
BiotechStockTrader.com - 26 minutes ago

The industry can be broadly called regenerative medicine, life sciences, biologics, stem cells and more. Regardless of the name, it is ubiquitously recognized as ...

View the full article

[ImmInst]

RegMed sector remains under pressure
Proactive Investors USA & Canada - Jun 4, 2012

The 6 W's: Who, what, where, when, why and what of it Mid-Day: The NASDAQ is DOWN -10.37 (-0.38%) to 2737.11 while the Dow is also DOWN -59.34 ...

View the full article

[ImmInst]

Osiris (OSIR) blasts even further as Aastrom (ASTM), Cytori (CYTX ...
Proactive Investors USA & Canada - Jun 18, 2012

The 6 W's: Who, what, where, when, why and what of it Mid-Day: The NASDAQ is UP +13.

View the full article

[ImmInst]

Bio-Tech Winners and Losers
Live Trading News - 2 hours ago

Bio-Tech Winners and Losers ALXA, GERN, NPSP, MDGN, DEPO, SNTA, ANTH, NLNK, ARNA, THER, RGEN Some of last Friday's Bio-Tech movers were up ...

View the full article

[ImmInst]

When you eat your own cooking, expect to be sick – once in a while ...
Proactive Investors USA & Canada - Jun 5, 2012

The 6 W's: Who, what, where, when, why and what of it Mid-Day: The NASDAQ is UP +4.95 (+0.18%) to 2764.96 while the Dow is also UP +4.05 (+0.003%) to ...

View the full article

[ImmInst]

Osiris Therapeutics: An Old Stem Cell Biotech Coming Of Age
Seeking Alpha - 1 hour ago

Osiris Therapeutics (OSIR) was founded way back in 1992, around the same time as Geron (GERN). Unlike its more famous competitor, Osiris has stayed in the stem cell game.

View the full article

[ImmInst]

Stem Cell Technology's Bright Future
Seeking Alpha - 2 hours ago

Stem Cell Technology's Bright Future. June 29, 2012 by: Tony Daltorio | includes: CUR, GERN, ISCO.OB, OSIR, STEM. It has been called the age of stem cells, the seemingly magic root cells of life that can be used to generate almost every other type of ...

View the full article

[ImmInst]

Continued weakness and no easing for the too small to matter or just the too ...
Proactive Investors USA & Canada - Jun 7, 2012

The 6 W's: Who, what, where, when, why and what of it Mid-Day: The NASDAQ is UP +6.11 (+0.21%) to 2850.83 while the Dow is also UP +93.39 (+0.75%) to 12508.18.

View the full article

[ImmInst]

Strategies You Need To Know To Invest In Speculative Biotech
Seeking Alpha - 1 hour ago

As most of my colleagues know, when it comes to investing one of my interests lie in speculative biotech holdings. Conquering the world's most debilitating diseases can be one of the most noble and profitable ventures for the companies and their investors.

View the full article

[ImmInst]

Lull or dull: RegMed sector slow to start with miniscule swings
Proactive Investors USA & Canada - Jul 18, 2012

The 6 W's: Who, what, where, when, why and what of it. The RegMed universe will continue to trade in a tight range this summer unless something extremely … positive or catastrophe … happens.

View the full article

[ImmInst]

Not all RegMed stocks are created equal as sentiment remains in the wallet
Proactive Investors USA & Canada - 12 hours ago

Not all RegMed stocks are created equal as sentiment remains in the wallet. Thu 3:12 pm by Henry McCusker. The 6 W's: Who, what, where, when, why and what of it.

View the full article

[ImmInst]

RegMed sector muddles up to earnings reporting
Proactive Investors USA & Canada - Jul 20, 2012

The 6 W's: Who, what, where, when, why and what of it. The RegMed universe earnings <LPS or Loss per Share> expectation is much lower.

View the full article

[ImmInst]

RegMed sector is starting to heat up on the Hot Tin Roof
Proactive Investors USA & Canada - Jul 24, 2012

RegMed sector is starting to heat up on the Hot Tin Roof. Tue 4:41 pm by Henry McCusker. The 6 W's: Who, what, where, when, why and what of it.

View the full article